2019
N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study
Li F, Welling MC, Johnson JA, Coughlin C, Mulqueen J, Jakubovski E, Coury S, Landeros-Weisenberger A, Bloch MH. N-Acetylcysteine for Pediatric Obsessive-Compulsive Disorder: A Small Pilot Study. Journal Of Child And Adolescent Psychopharmacology 2019, 30: 32-37. PMID: 31800306, PMCID: PMC7133418, DOI: 10.1089/cap.2019.0041.Peer-Reviewed Original ResearchConceptsCY-BOCS total scoreN-acetylcysteineYale-Brown ObsessiveTotal scorePlacebo groupNAC groupStudy populationBenefit of NACPlacebo-controlled clinical trialSymptom severityEffect of NACMild adverse eventsOCD symptom severityLarger study populationPediatric obsessive-compulsive disorderSmall pilot studyChildren's Yale-Brown ObsessiveStudy medicationAdverse eventsPrimary outcomeGlutamate dysfunctionObsessive-compulsive disorderWeek 12Future trialsNAC treatmentMeta-analysis of placebo group dropout in adult antidepressant trials
Li F, Nasir M, Olten B, Bloch MH. Meta-analysis of placebo group dropout in adult antidepressant trials. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2019, 98: 109777. PMID: 31697973, DOI: 10.1016/j.pnpbp.2019.109777.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderPlacebo leadAntidepressant trialsDiagnostic indicationsPlacebo-controlled trialStratified subgroup analysisBaseline illness severityMore study visitsDropout rateOverall dropout rateFreeman-Tukey transformationLonger trial durationEarlier publication yearPlacebo groupIllness severitySubgroup analysisDepressive disorderStudy visitMeta-AnalysisTrial durationAnxiety disordersTrialsEfficiency of trialsSubject burdenDisorders
2017
Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.
Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, Miguel EC, Shavitt RG. Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder. The Journal Of Clinical Psychiatry 2017, 78: e766-e773. PMID: 28617566, DOI: 10.4088/jcp.16m11101.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineAdolescentAdultAgedAnxiety DisordersComorbidityDepressive DisorderDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesPsychometricsSelective Serotonin Reuptake InhibitorsYoung AdultConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderY-BOCS scoresN-acetylcysteineNAC groupYale-Brown Obsessive Compulsive Scale scoresTreatment-resistant OCD patientsBaseline Y-BOCS scoresTreatment-Resistant ObsessivePrimary outcome measureAnxiety symptomsDSM-IV criteriaSymptom dimensionsCompulsive Scale scoresSpecific OCD symptom dimensionsOCD symptom dimensionsAntioxidant medicationsAbdominal painPlacebo groupGlutamate modulatorsSecondary outcomesTertiary hospitalOutpatient clinicSeverity scoreWeek 16
2016
Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder
Varigonda AL, Jakubovski E, Bloch MH. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry 2016, 55: 851-859.e2. PMID: 27663940, PMCID: PMC6944467, DOI: 10.1016/j.jaac.2016.07.768.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsPediatric obsessive-compulsive disorderSerotonin reuptake inhibitorsObsessive-compulsive disorderYale-Brown ObsessiveReuptake inhibitorsTime courseEarly treatment responseTreatment effectsChildren's Yale-Brown ObsessiveSSRI agentsPlacebo groupSSRI treatmentAdult patientsTreatment responsePooled estimatesPharmacological responseHigh dosesMeta-AnalysisSystematic reviewClomipramineSymptom dataMagnitude of responseMean differenceCompulsive Scale
2015
Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials
Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Coughlin CG, Leckman JF, Bloch MH. Meta-Analysis: Risk of Tics Associated With Psychostimulant Use in Randomized, Placebo-Controlled Trials. Journal Of The American Academy Of Child & Adolescent Psychiatry 2015, 54: 728-736. PMID: 26299294, DOI: 10.1016/j.jaac.2015.06.011.Peer-Reviewed Original ResearchConceptsWorsening of ticsRisk of ticsAttention-deficit/hyperactivity disorderPlacebo-controlled trialNew onsetDuration of treatmentPsychostimulant usePsychostimulant medicationNew-onset ticsType of psychostimulantsParallel-group trialStratified subgroup analysisSide effect dataTreatment of childrenAge of participantsPlacebo groupAdverse eventsCrossover studyPsychostimulant treatmentTic symptomsRisk ratioSubgroup analysisFamily historyGroup trialsPubMed searchSystematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder
Varigonda AL, Jakubovski E, Taylor MJ, Freemantle N, Coughlin C, Bloch MH. Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors in Pediatric Major Depressive Disorder. Journal Of The American Academy Of Child & Adolescent Psychiatry 2015, 54: 557-564. PMID: 26088660, DOI: 10.1016/j.jaac.2015.05.004.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsPediatric major depressive disorderMajor depressive disorderSerotonin reuptake inhibitorsSSRI agentsReuptake inhibitorsPediatric depressionDepressive disorderAdult major depressive disorderFirst-line pharmacological treatmentEarly treatment responseIndividual patient dataStandardized mean differenceMDD trialsSSRI doseSSRI pharmacotherapyPlacebo groupAdult patientsSSRI responsePharmacological treatmentPharmacological trialsTreatment responsePooled estimatesPharmacological responseHigh doses
2013
N-Acetylcysteine in the Treatment of Pediatric Trichotillomania: A Randomized, Double-Blind, Placebo-Controlled Add-On Trial
Bloch MH, Panza KE, Grant JE, Pittenger C, Leckman JF. N-Acetylcysteine in the Treatment of Pediatric Trichotillomania: A Randomized, Double-Blind, Placebo-Controlled Add-On Trial. Journal Of The American Academy Of Child & Adolescent Psychiatry 2013, 52: 231-240. PMID: 23452680, PMCID: PMC3745012, DOI: 10.1016/j.jaac.2012.12.020.Peer-Reviewed Original ResearchConceptsN-acetylcysteinePharmacological interventionsPediatric trichotillomaniaBenefit of NACBehavioral therapySecondary outcome measuresTreatment of childrenClinician-rated improvementMassachusetts General HospitalTreat populationPlacebo groupPrimary outcomeNAC groupGeneral HospitalOutcome measuresTreatment respondersSecondary measuresPlaceboTreatment assignmentTrichotillomaniaLinear mixed modelsTrialsSignificant differencesChildrenTherapy